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Mortality, malnutrition, and atherosclerosis in ESRD: What is cytes and endothelial cells. It is notable that whereas
the role of interleukin-6? There is growing evidence that in- most other cytokines function via paracrine/autocrine
creased plasma concentrations of CRP strongly predict cardio- mechanisms, the major effects of IL-6 are a consequencevascular death in both non-renal and renal patient populations.
of its concentration in the circulation and can take placeThe interleukin-6 (IL-6) system activity, which is the major
at sites distinct and far from its origin [3]. As the hepaticmediator of the acute phase response, is often markedly up-
regulated in uremic patients and has also been shown to predict synthesis of CRP is largely under the regulation of IL-6,
outcome. This raises the issue of whether or not IL-6 per se it is not surprising that the activity of this cytokine is
may contribute to increased mortality from malnutrition and also markedly up-regulated in ESRD patients [4–6].atherosclerotic cardiovascular disease in uremic patients. The
However, although most ESRD patients have elevatedcauses of elevated IL-6 levels in the uremic circulation are not
IL-6 levels, it should be pointed out that normal or evenfully understood, although a number of factors prevalent in
uremic patients, such as hypertension, adiposity, infections, low plasma levels of IL-6 could be found in dialysis
and chronic heart failure may all contribute. However, factors patients, suggesting that genetic factors might be of im-
associated with the dialysis procedure, such as bioincompatibil- portance. Indeed, recent findings suggest that certain
ity and non-sterile dialysate, may stimulate IL-6 production.
IL-6 promotor polymorphisms are associated with lowerFurthermore, available evidence suggests that genetic factors
levels of plasma IL-6 in healthy subjects [7] and peakmay also have an impact on circulating plasma IL-6 levels. We
advance the hypothesis that IL-6 may play a central role in IL-6 production after coronary artery bypass graft sur-
the genesis of inflammatory-driven malnutrition and that it gery [8].
may be regarded as a significant proatherogenic cytokine. This Since the first report by Bergstro¨m et al (abstract; J Am
hypothesis may provide a rationale to test if targeted anti-
Soc Nephrol 6:573A, 1995) of an association between ele-cytokine therapy may be one way to combat the unacceptable
vated CRP and outcome, several groups have reportedhigh cardiovascular mortality rate among dialysis patients.
similar findings in both hemodialysis (HD) [9] and peri-
toneal dialysis (PD) [10] patients. In view of the strong
association between CRP and IL-6, it is not surprisingChronic inflammation, as demonstrated by increased
that elevated IL-6 predicts cardiovascular morbidity [11]levels of various acute phase reactants such as C-reactive
and mortality [12] in non-renal patient groups. A studyprotein (CRP), has recently been shown to be a common
by Bologa et al [13] has shown that an elevated IL-6feature and also to predict outcome and cardiovascular
level predicts outcome also in dialysis patients. Similarly,disease in end-stage renal disease (ESRD) patients [1].
Kimmel et al [6] showed that higher levels of circulatingAlthough it is evident that a number of pro- and anti-
pro-inflammatory cytokines such as IL-6 are associatedinflammatory cytokines such as interleukin (IL)-1, IL-10,
with mortality, whereas cytokines reflecting improvedand tumor necrosis factor- (TNF-) as well as soluble
T-cells function are associated with a survival advantage.cytokine receptors orchestrate the inflammatory re-
In ESRD patients starting dialysis treatment, we simi-sponse [2], available data suggest that IL-6 plays a key
larly observed that elevated IL-6 levels were significantlyrole in these events. IL-6 belongs to a family of 20 kD
associated with poor outcome (Fig. 1).polypeptide cytokines that are secreted from a number
of different cells, including fibroblasts, adipocytes, mono-
CAUSES OF ELEVATED IL-6 LEVELS IN
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mortality. The potential causes of elevated plasma IL-6 levels in
ESRD patients are many. Kaizu et al [14] showed that 2002 by the International Society of Nephrology
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IL-6 are increased in patients with CHF and that local
and systemic effects of pro-inflammatory cytokines may
have an important role in the pathogenesis of CHF [23].
It has been reported that changes in IL-6 and CRP are
dynamic and that increased levels occur mainly with de-
compensated CHF [24]. Thus, it is important to distin-
guish between compensated and decompensated CHF
when studying circulatory plasma levels of acute phase
reactants and cytokines. As cardiac cachexia is a strong
independent risk factor for mortality in non-renal pa-
tients with CHF [25], it seems conceivable that CHF
may contribute to wasting, elevated levels of IL-6, and
increased mortality also in ESRD patients.
Recently, a significant graded relationship between
blood pressure and plasma levels of ICAM-1 [26] andFig. 1. Kaplan-Meier survival analysis showing the outcome of 147
IL-6 [26, 27] were observed in apparently healthy sub-ESRD patients followed after start of renal replacement therapy. The
patient material is divided into quartiles according to basal levels of jects. Based on these observations and the documented
interleukin-6. The survival rate is statistically different (Chi-square 27.5; high prevalence of hypertension in ESRD, it could be spec-P  0.00001) between the groups.
ulated that poor blood pressure control might be another
factor causing elevated IL-6 levels. Also increased total
fat mass may be a cause of elevated IL-6 levels in ESRD
multiple factors, such as long-term HD, age, and the patients because production of IL-6 occurs in adipose
use of regenerated cellulose membrane dialyzer were tissue [28]. As obesity is commonly associated with insu-
associated with elevated IL-6. However, as a recent study lin resistance, it is not surprising that an inverse associa-
showed that IL-6 production does not increase with age tion between insulin sensitivity and IL-6 has been found
per se [15], it could be postulated that co-morbid factors [27]. Although accumulating data suggest that various
associated with age are the main cause of elevated IL-6 persistent infections, such as Chlamydia pneumoniae, are
levels. Indeed, a number of factors prevalent in ESRD associated with atherosclerosis, the mechanisms behind
patients, such as chronic heart failure (CHF), high blood this association remain unclear. However, as it recently
pressure, increased body fat mass, insulin resistance, and was demonstrated that the acellular components of Chla-
chronic infections, have recently been shown to be asso- mydia pneumoniae are potent stimuli for IL-6 production
ciated with increased IL-6 levels. [29], this may be one mechanism by which chlamydial
infection causes atherosclerosis. This hypothesis is sup-
Non-dialysis related factors that may cause elevated ported by two recent clinical studies, which showed an
IL-6 levels association between serological evidence of persistent
Because some studies have shown no difference in the chlamydial infection, carotid atherosclerosis, and ele-
circulatory levels of IL-1, IL-6, and TNF- between long- vated IL-6 levels in ESRD patients, (abstract; Kato et
term and not yet dialyzed patients, this suggests that the al, J Am Soc Nephrol 12:389A, 2001) [30].
uremic syndrome per se may be a more important cause
Dialysis-related factors that may cause elevatedof elevated cytokine levels than the dialysis procedure
IL-6 levels[16, 17]. This may partly be caused by the fact that ESRD
patients have a lower urinary IL-6 receptor excretion Although Herbelin et al [5] found no difference in
than controls [18]. Indeed, the deterioration of renal IL-6 activity between long-term and not yet dialyzed
function has been shown to be associated with a signifi- patients, others have found elevated IL-6 levels in dial-
cant increase in serum cytokine levels [19], and a strong ysis patients compared with ESRD patients not yet on
positive correlation between creatinine clearance and dialysis [4, 31]. This suggests that the dialysis procedure
various cytokines and their soluble receptors has been per se induces an acute inflammatory reaction and gener-
found in undialyzed patients with varying degree of renal ation of IL-6. Indeed, Takahashi et al [32] demonstrated
failure [20]. Bolton et al [21] found in a multiple regres- that both HD and PD generate an increase in blood
sion analysis that serum creatinine was the sole determi- mononuclear cell IL-6 mRNA expression and plasma
nant of IL-6 levels in a group of predialysis and dialysis IL-6 levels. Kaul et al [33] has demonstrated that the
patients. Similarly, Panichi et al [22] recently demon- initiation of HD leads to a significant improvement of
strated that both CRP and IL-6 levels are related to in vitro T-cell function. However, in this study it was
renal function in predialysis patients. notable that the expected normalization of IL-6 produc-
tion did not occur, which may be the result of cytokineClinical studies have shown that circulating levels of
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Table 1. Possible causes of elevated interleukin-6 levels
in ESRD patients
Factor Reference
Non-dialysis related factors
Hypertension [27]
Increased fat mass [28]
Insulin resistance [27]
Persistent infections (such as chlamydia pneumoniae) [29]
Chronic heart failure [24]
Decreased residual renal function [21, 22]
Genetic factors [7]
Dialysis related factors
Bioincompatibility [18]
Unpure dialysate [34]
Backfiltration [35]
Fig. 2. Regression analyses showing a positive correlation (R  0.44;
P  0.01) between Log interleukin-6 and soluble intracellular adhesion
molecule (sICAM-1) levels in 48 ESRD patients close to start of dialysisinduction of the dialysis membrane [33]. Several factors
treatment.
related to HD have been proposed to contribute to the
generation of IL-6 and/or enhance the inflammatory ef-
fect of IL-6, dialysis against bioincompatible membrane
[18], the use of non-sterile dialysate [34], and backfiltra- mechanisms recently reviewed by Yudkin et al [3]. In
tion [35]. There is as yet little available evidence in the this respect, it is of interest that both TNF- and IL-6
literature regarding the effects of PD on the generation inhibit lipoprotein lipase production in adipocyte cell
of cytokines. However, the systemic inflammatory effects lines [39], thus mediating lipolysis and dyslipidemia [40].
of PD may be similar to those observed in HD as Libetta Further support for the concept that IL-6 may be more
et al [31] found that PD induces activation of monocytes than just a marker of atherosclerosis may be derived
with an enhanced release of IL-6. We (abstract; J Am from a recent study showing that increased IL-6 expres-
Soc Nephrol 12:438A, 2001) have recently observed an sion is involved at the fibrous plaque stage of the athero-
association between peritoneal transport rate for small sclerotic process [41]. Finally, a recent clinical study
solutes and both plasma and intraperitoneal lL-6 levels, demonstrated that elevated circulating IL-6 levels were
suggesting that systemic and intraperitoneal inflamma- independently associated with progressive carotid ath-
tion may be involved in the pathophysiology of high erosclerosis during the first 12 months of dialysis treat-
peritoneal transport status in PD patients. ment [30].
HOW COULD IL-6 INCREASE RISK OF
OTHER CYTOKINES AND THECARDIOVASCULAR DISEASE?
ATHEROGENIC PROCESS
In the past couple of years, there has been a shift in
It should be pointed out that other pro-inflammatorythe general view of the origin of atherosclerosis. The cur-
cytokines also might affect the atherogenic process. Forrent understanding is that an inflammatory process in-
example, it has been shown that TNF- may be the keyvolving the acute phase response, a biological response
cytokine mediating endothelial dysfunction [42] and into various disturbances such as infection, tissue injury,
vitro vascular calcification [43]. The latter effect of TNF-or immune disturbance, is a primary event [36]. As a
could be one possible link in the documented associationrecent study has shown that injection of recombinant
between inflammation, malnutrition, and cardiac valveIL-6 exacerbates early atherosclerosis in apoE-deficient
calcification recently documented in PD patients [44]. Itmice, the role of IL-6 in this process may be important
should also be mentioned that various anti-inflammatory[37]. Indeed, several lines of evidence suggest that IL-6
cytokines, such as IL-10, might have protective proper-is a significant proatherogenic cytokine. First, elevated
ties in the atherosclerotic process. Girndt et al [45] havelevels of IL-6 are a primary stimulant of soluble intercel-
postulated that the secretion of IL-10 might be regardedlular adhesion molecule-1 (sICAM-1), which mediates
as a compensatory mechanism that controls monokinethe attachment and migration of leukocytes across the
induction and that patients unable to enhance IL-10 syn-endothelial surface [38]. We have found a strong positive
thesis are at risk. Indeed, Smith et al [46] recently demon-association between IL-6 and sICAM-1 in ESRD pa-
strated that the serum levels of IL-10 are decreased intients supporting this hypothesis (Fig. 2). Second, IL-6
patients with unstable angina pectoris, and Girndt et almay contribute to the development of atherosclerosis
through various metabolic, endothelial, and coagulant (abstract; J Am Soc Nephrol 12:380A, 2001) have re-
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ported that the IL-10 genotype influenced the risk of atherogenic properties, it could be speculated that vari-
cardiovascular events in 300 HD patients. ous treatment strategies inhibiting IL-6 production could
decrease cardiovascular morbidity and mortality. For ex-
ample, Schouten et al [56] reported that, whereas theNUTRITIONAL STATUS IS AFFECTED BY IL-6
use of a bioincompatible dialyzer membrane (Cupram-Disturbances in protein and energy metabolism, hor-
monium) was associated with increased IL-6 levels, themonal derangements, and a spontaneous reduction in
use of a biocompatible membrane (Polysulfon) was not.dietary energy and protein intake may be responsible
Moreover, Schiffl et al [34] have shown that a changefor the decline in nutritional status with progressive renal
from conventional to ultrapure dialysis fluid reduced thefailure. Little is known about the specific mechanism(s)
levels of IL-6 and improved nutritional status in HDresponsible for the altered appetite and metabolism in
patients. In addition, other treatment regimens, such asrenal disease, although a role for pro-inflammatory cyto-
ACE-inhibitors [57] and vitamin E [58], which have beenkines has been proposed [47]. In elderly patients without
shown to decrease IL-6 levels in plasma or monocytes inrenal disease, cachexia is usually associated with higher-
non-renal patient groups, should be considered in ESRDthan-normal concentrations of TNF-, IL-1, and IL-6
patients. Recently, cytokine-blocking agents, such as[48]. An important role for IL-6 in this scenario could
monoclonal antibodies, soluble receptors, and receptorbe proposed, as it stimulates the breakdown of muscle
protein [49], activates cathepsin activity [50], and pro- antagonists, have been explored as therapeutic agents
motes cancer cachexia [51]. Moreover, IL-6 receptor an- for patients with rheumatoid arthritis (RA). Injections
tibody has been shown to inhibit muscle atrophy in IL-6 of anti-IL-6 monoclonal antibodies have been associated
transgenic mice [52]. Also, clinical data suggest a signifi- with improvement in clinical variables as well as reduced
cant role for IL-6 in mediating malnutrition in ESRD acute-phase protein in RA patients [59]. It would there-
patients. Increased levels of IL-6 predict hypoalbumin- fore be of interest to study the effect of targeted anti-IL-6
emia [13, 30] and are associated with various markers treatment on inflammatory and nutritive parameters as
of malnutrition in cross-sectional analyses [14, 30, 53]. well as outcome in ESRD patients. However, as the
Finally, Kaizu et al [14] showed that the body weight effects of IL-6 are complex and interrelated to local and
loss over 3 years was significantly higher, and serum systemic concentrations of other pro- and anti-inflam-
albumin levels were significantly lower in dialysis pa-
matory cytokines (e.g. TNF-, IL-1, and IL-10), targetedtients with high IL-6 levels.
anti-IL-6 therapy may turn out to have only minor clini-Although pro-inflammatory cytokines may predomi-
cal effects.nantly cause malnutrition by increased protein catabo-
lism, they also affect appetite and eating behavior. The
mechanism of cytokine-induced anorexia is not clear, al- CONCLUSION
though some studies have implicated a role of elevated
Interleukin-6, the major mediator of the acute phaseleptin. Interestingly, both leptin and its receptor share
response, is elevated in most, but not all, ESRD patientsstructural and functional similarities with the IL-6 family
and predicts outcome. A number of factors prevalent inof cytokines. Grunfeld et al [54] found that administra-
patients with ESRD, such as hypertension, adiposity,tion of cytokines increased leptin mRNA levels in ham-
insulin resistance, CHF, and persistent infections couldsters and noted a strong inverse correlation between
all be associated with elevated IL-6 levels. However,leptin mRNA level and subsequent food intake. Un-
factors associated with the dialysis procedure, such asfortunately, available data regarding the association
between inflammation and leptin are conflicting in hu- bioincompatibility and non-sterile dialysis fluids, also
mans. Whereas Fouque et al (abstract; J Am Soc Nephrol may stimulate IL-6 production. Although patterns of
12:355A, 2001) have presented data showing a signifi- cytokines and their interactions may be more important
cant positive relation between IL-6 and serum leptin than individual circulatory plasma levels, we advance
in HD patients, Don et al [55] demonstrated that leptin the hypothesis that increased IL-6 levels may adversely
levels might actually be suppressed during inflammation. affect nutritional status and have pro-atherogenic prop-
Thus, it is obvious that more studies are needed, espe- erties in ESRD patients.
cially in humans, to test if pro-inflammatory cytokines
Reprint requests to Peter Stenvinkel, M.D., Department of Nephrol-mediate anorexia directly at hypothalamic nuclei, indi-
ogy K56, Huddinge University Hospital, 141 86 Stockholm, Sweden.rectly through leptin, or by other mechanisms.
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